Symbols / PFE
PFE Chart
About
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. has strategic collaboration with Boltz, PBC to develop and deploy state-of-the-art biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Gen | Market Cap | 155.66B |
| Enterprise Value | 202.86B | Income | 7.75B | Sales | 62.58B |
| Book/sh | 16.32 | Cash/sh | 2.64 | Dividend Yield | 6.28% |
| Payout | 126.47% | Employees | — | IPO | — |
| P/E | 20.13 | Forward P/E | 9.69 | PEG | — |
| P/S | 2.49 | P/B | 1.68 | P/C | — |
| EV/EBITDA | 7.90 | EV/Sales | 3.24 | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | 66.53 | LT Debt/Eq | — |
| EPS (ttm) | 1.36 | EPS next Y | 2.83 | EPS Growth | — |
| Revenue Growth | -1.20% | Earnings | 2026-04-28 | ROA | — |
| ROE | 8.58% | ROIC | — | Gross Margin | 75.81% |
| Oper. Margin | 24.63% | Profit Margin | 12.42% | Shs Outstand | 5.69B |
| Shs Float | 5.68B | Short Float | 2.52% | Short Ratio | 3.00 |
| Short Interest | — | 52W High | 27.94 | 52W Low | 20.92 |
| Beta | 0.44 | Avg Volume | 50.36M | Volume | 18.16M |
| Target Price | $28.63 | Recom | Buy | Prev Close | $27.37 |
| Price | $27.38 | Change | 0.03% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$28.71
Mean price target
2. Current target
$27.37
Latest analyst target
3. DCF / Fair value
$20.40
Fallback: EPS × 15 (assumed fair P/E). No FCF data; use with …
Ratings
Current target
$27.37
Low
$25.00
High
$35.46
Mean
$28.71
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-04 | reit | Cantor Fitzgerald | Neutral → Neutral | $27 |
| 2026-01-27 | main | Cantor Fitzgerald | Neutral → Neutral | $27 |
| 2025-12-17 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $27 |
| 2025-12-15 | main | B of A Securities | Neutral → Neutral | $28 |
| 2025-12-12 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $28 |
| 2025-11-24 | main | Guggenheim | Buy → Buy | $35 |
| 2025-10-10 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $32 |
| 2025-10-03 | main | B of A Securities | Neutral → Neutral | $30 |
| 2025-08-06 | main | Citigroup | Neutral → Neutral | $26 |
| 2025-08-06 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $33 |
| 2025-08-06 | main | B of A Securities | Neutral → Neutral | $28 |
| 2025-04-30 | main | UBS | Neutral → Neutral | $25 |
| 2025-04-22 | init | Cantor Fitzgerald | — → Neutral | $24 |
| 2025-04-08 | main | UBS | Neutral → Neutral | $24 |
| 2025-04-08 | down | Goldman Sachs | Buy → Neutral | $25 |
| 2025-03-18 | reit | Guggenheim | Buy → Buy | — |
| 2025-03-12 | reit | Guggenheim | Buy → Buy | — |
| 2025-02-10 | reit | Guggenheim | Buy → Buy | $33 |
| 2025-02-05 | main | UBS | Neutral → Neutral | $28 |
| 2025-01-28 | main | Citigroup | Neutral → Neutral | $29 |
News
RSS: Latest PFE news- Is There 25% Downside For Pfizer Stock? - Forbes Wed, 18 Feb 2026 16
- Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game - Seeking Alpha Wed, 18 Feb 2026 16
- Monthly HIV shots outperform daily pills for people with adherence challenges - Stock Titan Wed, 18 Feb 2026 22
- Essex Financial Services Inc. Trims Stock Holdings in Pfizer Inc. $PFE - MarketBeat Wed, 18 Feb 2026 11
- Fund Update: New $64.7M $PFE stock position opened by TCW GROUP INC - Quiver Quantitative ue, 17 Feb 2026 19
- Pfizer (PFE) Valuation Check After Recent Share Price Rebound And Mixed Earnings Signals - Yahoo Finance Singapore Wed, 18 Feb 2026 13
- Did Pfizer's Obesity Shot Do Well Enough To Catch Lilly? - Investor's Business Daily ue, 03 Feb 2026 08
- NIH director being tapped as acting CDC director (PFE:NYSE) - Seeking Alpha Wed, 18 Feb 2026 19
- Pfizer Stock (PFE) Opinions on Market Rotation to Defensives - Quiver Quantitative Sun, 15 Feb 2026 14
- Skandinaviska Enskilda Banken AB publ Trims Stock Holdings in Pfizer Inc. $PFE - MarketBeat Wed, 18 Feb 2026 10
- Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4? - Yahoo Finance Mon, 09 Feb 2026 08
- Pfizer drug combo slows metastatic colorectal cancer in major trial - Stock Titan ue, 17 Feb 2026 11
- Pfizer: The Rebound Looks Unsustainable (NYSE:PFE) - Seeking Alpha ue, 17 Feb 2026 22
- Advisors Capital Management LLC Purchases 260,742 Shares of Pfizer Inc. $PFE - MarketBeat Wed, 18 Feb 2026 11
- Is Pfizer Inc. (PFE) One of the Best Medical Research Stocks to Buy According to Hedge Funds? - Yahoo Finance Fri, 13 Feb 2026 14
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5583 | — | — | Stock Award(Grant) at price 0.00 per share. | DAMICO JENNIFER B. | Officer | — | 2025-03-04 00:00:00 | D |
| 1 | 2500 | 64825 | — | Sale at price 25.93 per share. | DAMICO JENNIFER B. | Officer | — | 2025-03-04 00:00:00 | D |
| 2 | 582823 | 18248188 | — | Conversion of Exercise of derivative security at price 31.31 per share. | BOURLA ALBERT | Chief Executive Officer | — | 2025-02-27 00:00:00 | D |
| 3 | 22416 | 701845 | — | Conversion of Exercise of derivative security at price 31.31 per share. | DAMICO JENNIFER B. | Officer | — | 2025-02-27 00:00:00 | D |
| 4 | 19054 | 596581 | — | Conversion of Exercise of derivative security at price 31.31 per share. | SAHNI PAYAL | Officer | — | 2025-02-27 00:00:00 | D |
| 5 | 48419 | 1515999 | — | Conversion of Exercise of derivative security at price 31.31 per share. | MCDERMOTT MICHAEL | Officer | — | 2025-02-27 00:00:00 | D |
| 6 | 17450 | — | — | Stock Award(Grant) at price 0.00 per share. | BOSHOFF CHRISTOFFEL | Officer | — | 2025-02-27 00:00:00 | D |
| 7 | 85182 | 2667048 | — | Conversion of Exercise of derivative security at price 31.31 per share. | SUSMAN SALLY | Officer | — | 2025-02-27 00:00:00 | D |
| 8 | 72629 | 2274014 | — | Conversion of Exercise of derivative security at price 31.31 per share. | FONSECA LIDIA PH.D. | Officer | — | 2025-02-27 00:00:00 | D |
| 9 | 156914 | 4912977 | — | Conversion of Exercise of derivative security at price 31.31 per share. | LANKLER DOUGLAS M | Officer | — | 2025-02-27 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -939.96M | -872.13M | -293.86M | 22.65M |
| TaxRateForCalcs | 0.21 | 0.21 | 0.10 | 0.08 |
| NormalizedEBITDA | 22.60B | 13.71B | 44.09B | 30.50B |
| TotalUnusualItems | -4.48B | -4.15B | -3.06B | 298.00M |
| TotalUnusualItemsExcludingGoodwill | -4.48B | -4.15B | -3.06B | 298.00M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 8.02B | 2.13B | 31.37B | 22.41B |
| ReconciledDepreciation | 7.01B | 6.29B | 5.06B | 5.19B |
| ReconciledCostOfRevenue | 16.12B | 23.40B | 32.89B | 29.33B |
| EBITDA | 18.13B | 9.56B | 41.03B | 30.79B |
| EBIT | 11.11B | 3.27B | 35.97B | 25.60B |
| NetInterestIncome | -2.55B | -585.00M | -987.00M | -1.25B |
| InterestExpense | 3.09B | 2.21B | 1.24B | 1.29B |
| InterestIncome | 545.00M | 1.62B | 251.00M | 36.00M |
| NormalizedIncome | 11.56B | 5.41B | 34.13B | 22.14B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 8.03B | 2.12B | 31.37B | 21.98B |
| TotalExpenses | 48.80B | 55.33B | 64.01B | 61.05B |
| DilutedAverageShares | 5.70B | 5.71B | 5.73B | 5.71B |
| BasicAverageShares | 5.66B | 5.64B | 5.61B | 5.60B |
| DilutedEPS | 1.41 | 0.37 | 5.47 | 3.85 |
| BasicEPS | 1.42 | 0.38 | 5.59 | 3.92 |
| DilutedNIAvailtoComStockholders | 8.03B | 2.12B | 31.37B | 21.98B |
| NetIncomeCommonStockholders | 8.03B | 2.12B | 31.37B | 21.98B |
| NetIncome | 8.03B | 2.12B | 31.37B | 21.98B |
| MinorityInterests | -31.00M | -39.00M | -35.00M | -45.00M |
| NetIncomeIncludingNoncontrollingInterests | 8.06B | 2.16B | 31.41B | 22.02B |
| NetIncomeDiscontinuousOperations | 11.00M | -15.00M | 6.00M | -434.00M |
| NetIncomeContinuousOperations | 8.05B | 2.17B | 31.40B | 22.46B |
| TaxProvision | -28.00M | -1.11B | 3.33B | 1.85B |
| PretaxIncome | 8.02B | 1.06B | 34.73B | 24.31B |
| OtherIncomeExpense | -4.26B | -2.58B | -1.45B | 5.33B |
| OtherNonOperatingIncomeExpenses | 113.00M | 1.07B | 1.18B | 4.56B |
| SpecialIncomeCharges | -5.76B | -6.22B | -2.10B | -1.21B |
| GainOnSaleOfPPE | 0.00 | 99.00M | ||
| GainOnSaleOfBusiness | 525.00M | 222.00M | ||
| OtherSpecialCharges | 567.00M | 474.00M | 230.00M | 182.00M |
| WriteOff | 432.00M | 227.00M | 52.00M | 53.00M |
| ImpairmentOfCapitalAssets | 3.29B | 3.02B | 421.00M | 86.00M |
| RestructuringAndMergernAcquisition | 2.42B | 2.94B | 1.45B | 944.00M |
| EarningsFromEquityInterest | 102.00M | 505.00M | 436.00M | 471.00M |
| GainOnSaleOfSecurity | 1.28B | 2.07B | -959.00M | 1.51B |
| NetNonOperatingInterestIncomeExpense | -2.55B | -585.00M | -987.00M | -1.25B |
| InterestExpenseNonOperating | 3.09B | 2.21B | 1.24B | 1.29B |
| InterestIncomeNonOperating | 545.00M | 1.62B | 251.00M | 36.00M |
| OperatingIncome | 14.83B | 4.22B | 37.16B | 20.23B |
| OperatingExpense | 30.95B | 30.38B | 29.67B | 30.23B |
| DepreciationAmortizationDepletionIncomeStatement | 5.29B | 4.73B | 3.61B | 3.70B |
| DepreciationAndAmortizationInIncomeStatement | 5.29B | 4.73B | 3.61B | 3.70B |
| Amortization | 5.29B | 4.73B | 3.61B | 3.70B |
| AmortizationOfIntangiblesIncomeStatement | 5.29B | 4.73B | 3.61B | 3.70B |
| ResearchAndDevelopment | 10.93B | 10.87B | 12.38B | 13.83B |
| SellingGeneralAndAdministration | 14.73B | 14.77B | 13.68B | 12.70B |
| GrossProfit | 45.78B | 34.60B | 66.83B | 50.47B |
| CostOfRevenue | 17.85B | 24.95B | 34.34B | 30.82B |
| TotalRevenue | 63.63B | 59.55B | 101.17B | 81.29B |
| OperatingRevenue | 63.63B | 59.55B | 101.17B | 81.29B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 3.93B | 3.92B | 3.90B | 3.85B |
| OrdinarySharesNumber | 5.67B | 5.65B | 5.62B | 5.62B |
| ShareIssued | 9.59B | 9.56B | 9.52B | 9.47B |
| NetDebt | 62.61B | 67.99B | 34.44B | 35.05B |
| TotalDebt | 63.65B | 70.84B | 34.86B | 37.00B |
| TangibleBookValue | -35.74B | -43.67B | 916.00M | 2.85B |
| InvestedCapital | 151.85B | 159.86B | 130.52B | 114.20B |
| WorkingCapital | 7.36B | -4.46B | 9.12B | 17.02B |
| NetTangibleAssets | -35.74B | -43.67B | 916.00M | 2.85B |
| CommonStockEquity | 88.20B | 89.01B | 95.66B | 77.20B |
| TotalCapitalization | 144.91B | 149.51B | 127.59B | 111.96B |
| TotalEquityGrossMinorityInterest | 88.50B | 89.29B | 95.92B | 77.46B |
| MinorityInterest | 294.00M | 274.00M | 256.00M | 262.00M |
| StockholdersEquity | 88.20B | 89.01B | 95.66B | 77.20B |
| OtherEquityInterest | 1.00M | |||
| GainsLossesNotAffectingRetainedEarnings | -7.84B | -7.96B | -8.30B | -5.90B |
| OtherEquityAdjustments | 57.00M | -217.00M | -412.00M | 119.00M |
| ForeignCurrencyTranslationAdjustments | -7.98B | -7.86B | -8.36B | -6.17B |
| MinimumPensionLiabilities | 191.00M | 128.00M | 248.00M | 377.00M |
| UnrealizedGainLoss | -106.00M | -9.00M | 220.00M | -220.00M |
| TreasuryStock | 114.76B | 114.49B | 113.97B | 111.36B |
| RetainedEarnings | 116.72B | 118.35B | 125.66B | 103.39B |
| AdditionalPaidInCapital | 93.60B | 92.63B | 91.80B | 90.59B |
| CapitalStock | 480.00M | 478.00M | 476.00M | 473.00M |
| CommonStock | 480.00M | 478.00M | 476.00M | 473.00M |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 124.90B | 137.21B | 101.29B | 104.01B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 81.90B | 89.42B | 59.15B | 61.34B |
| OtherNonCurrentLiabilities | 14.15B | 16.54B | 13.18B | 9.74B |
| DerivativeProductLiabilities | 701.00M | 1.04B | 959.00M | 1.44B |
| EmployeeBenefits | 2.12B | 2.17B | 2.25B | 3.72B |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 2.12B | 2.17B | 2.25B | 3.72B |
| TradeandOtherPayablesNonCurrent | 6.11B | 8.53B | 9.81B | 11.33B |
| NonCurrentDeferredLiabilities | 2.12B | 640.00M | 1.02B | 349.00M |
| NonCurrentDeferredTaxesLiabilities | 2.12B | 640.00M | 1.02B | 349.00M |
| LongTermDebtAndCapitalLeaseObligation | 56.70B | 60.50B | 31.93B | 34.76B |
| LongTermDebt | 56.70B | 60.50B | 31.93B | 34.76B |
| CurrentLiabilities | 42.99B | 47.79B | 42.14B | 42.67B |
| OtherCurrentLiabilities | 19.72B | 20.54B | 22.58B | 24.94B |
| CurrentDeferredLiabilities | 1.51B | 2.70B | 2.52B | 3.07B |
| CurrentDeferredRevenue | 1.51B | 2.70B | 2.52B | 3.07B |
| CurrentDebtAndCapitalLeaseObligation | 6.95B | 10.35B | 2.93B | 2.24B |
| CurrentDebt | 6.95B | 10.35B | 2.93B | 2.24B |
| OtherCurrentBorrowings | 4.49B | 2.38B | 2.93B | 2.24B |
| CommercialPaper | 2.45B | 7.96B | 0.00 | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.84B | 2.78B | 3.41B | 3.33B |
| PayablesAndAccruedExpenses | 10.98B | 11.43B | 10.70B | 9.09B |
| Payables | 10.98B | 11.43B | 10.70B | 9.09B |
| DividendsPayable | 2.44B | 2.37B | 2.30B | 2.25B |
| TotalTaxPayable | 2.91B | 2.35B | 1.59B | 1.27B |
| IncomeTaxPayable | 2.91B | 2.35B | 1.59B | 1.27B |
| AccountsPayable | 5.63B | 6.71B | 6.81B | 5.58B |
| TotalAssets | 213.40B | 226.50B | 197.21B | 181.48B |
| TotalNonCurrentAssets | 163.04B | 183.17B | 145.94B | 121.78B |
| OtherNonCurrentAssets | 9.82B | 12.47B | 13.16B | 7.68B |
| NonCurrentDeferredAssets | 8.66B | 3.71B | 6.69B | 3.34B |
| NonCurrentDeferredTaxesAssets | 8.66B | 3.71B | 6.69B | 3.34B |
| InvestmentsAndAdvances | 2.23B | 15.37B | 15.07B | 21.53B |
| OtherInvestments | 5.05B | |||
| InvestmentinFinancialAssets | 2.01B | 3.73B | 4.04B | 5.05B |
| HeldToMaturitySecurities | 45.00M | 47.00M | 48.00M | 34.00M |
| AvailableForSaleSecurities | 1.97B | 3.68B | 3.99B | 5.02B |
| LongTermEquityInvestment | 217.00M | 11.64B | 11.03B | 16.47B |
| GoodwillAndOtherIntangibleAssets | 123.94B | 132.68B | 94.75B | 74.35B |
| OtherIntangibleAssets | 55.41B | 64.90B | 43.37B | 25.15B |
| Goodwill | 68.53B | 67.78B | 51.38B | 49.21B |
| NetPPE | 18.39B | 18.94B | 16.27B | 14.88B |
| AccumulatedDepreciation | -16.48B | -16.05B | -15.17B | -15.07B |
| GrossPPE | 34.88B | 34.98B | 31.45B | 29.96B |
| ConstructionInProgress | 4.94B | 5.92B | 4.88B | 3.82B |
| OtherProperties | 1.00M | -1.00M | 1.00M | |
| MachineryFurnitureEquipment | 20.61B | 19.66B | 17.37B | 16.71B |
| BuildingsAndImprovements | 9.04B | 9.05B | 8.83B | 9.00B |
| LandAndImprovements | 291.00M | 353.00M | 368.00M | 423.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 50.36B | 43.33B | 51.26B | 59.69B |
| OtherCurrentAssets | 4.25B | 4.91B | 5.02B | 3.82B |
| Inventory | 10.85B | 10.19B | 8.98B | 9.06B |
| OtherInventories | -1.00M | -1.00M | ||
| FinishedGoods | 3.77B | 3.50B | 2.60B | 3.64B |
| WorkInProcess | 6.10B | 5.69B | 5.52B | 4.42B |
| RawMaterials | 976.00M | 1.01B | 859.00M | 994.00M |
| Receivables | 14.78B | 15.54B | 14.53B | 15.74B |
| TaxesReceivable | 3.31B | 3.98B | 3.58B | 4.27B |
| AccountsReceivable | 11.46B | 11.57B | 10.95B | 11.48B |
| AllowanceForDoubtfulAccountsReceivable | -438.00M | -470.00M | -449.00M | -492.00M |
| GrossAccountsReceivable | 11.90B | 12.04B | 11.40B | 11.97B |
| CashCashEquivalentsAndShortTermInvestments | 20.48B | 12.69B | 22.73B | 31.07B |
| OtherShortTermInvestments | 19.43B | 9.84B | 22.32B | 29.12B |
| CashAndCashEquivalents | 1.04B | 2.85B | 416.00M | 1.94B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 9.84B | 4.79B | 26.03B | 29.87B |
| RepurchaseOfCapitalStock | 0.00 | 0.00 | -2.00B | 0.00 |
| RepaymentOfDebt | -16.07B | -2.57B | -7.41B | -2.10B |
| IssuanceOfDebt | 8.91B | 38.52B | 3.89B | 997.00M |
| CapitalExpenditure | -2.91B | -3.91B | -3.24B | -2.71B |
| InterestPaidSupplementalData | 3.23B | 2.21B | 1.44B | 1.47B |
| IncomeTaxPaidSupplementalData | 3.60B | 3.15B | 7.87B | 7.43B |
| EndCashPosition | 1.11B | 2.92B | 468.00M | 1.98B |
| BeginningCashPosition | 2.92B | 468.00M | 1.98B | 1.82B |
| EffectOfExchangeRateChanges | -66.00M | -40.00M | -165.00M | -59.00M |
| ChangesInCash | -1.74B | 2.49B | -1.35B | 217.00M |
| FinancingCashFlow | -17.14B | 26.07B | -14.83B | -9.82B |
| CashFromDiscontinuedFinancingActivities | 0.00 | 0.00 | ||
| CashFlowFromContinuingFinancingActivities | -17.14B | 26.07B | -14.83B | -9.82B |
| NetOtherFinancingCharges | -469.00M | -632.00M | -335.00M | 16.00M |
| CashDividendsPaid | -9.51B | -9.25B | -8.98B | -8.73B |
| CommonStockDividendPaid | -9.51B | -9.25B | -8.98B | -8.73B |
| NetCommonStockIssuance | 0.00 | 0.00 | -2.00B | 0.00 |
| CommonStockPayments | 0.00 | 0.00 | -2.00B | 0.00 |
| NetIssuancePaymentsOfDebt | -7.16B | 35.95B | -3.52B | -1.10B |
| NetShortTermDebtIssuance | -4.91B | 7.68B | -218.00M | -96.00M |
| ShortTermDebtPayments | -13.82B | -3.00M | -4.11B | -96.00M |
| ShortTermDebtIssuance | 8.91B | 7.69B | 3.89B | 0.00 |
| NetLongTermDebtIssuance | -2.25B | 28.26B | -3.30B | -1.01B |
| LongTermDebtPayments | -2.25B | -2.57B | -3.30B | -2.00B |
| LongTermDebtIssuance | 0.00 | 30.83B | 0.00 | 997.00M |
| InvestingCashFlow | 2.65B | -32.28B | -15.78B | -22.55B |
| CashFromDiscontinuedInvestingActivities | 0.00 | 0.00 | -12.00M | |
| CashFlowFromContinuingInvestingActivities | 2.65B | -32.28B | -15.78B | -22.53B |
| NetOtherInvestingChanges | -180.00M | -192.00M | -306.00M | |
| DividendsReceivedCFI | 0.00 | 0.00 | 3.96B | 0.00 |
| NetInvestmentPurchaseAndSale | -1.48B | 15.24B | 6.68B | -19.52B |
| SaleOfInvestment | 8.83B | 46.42B | 45.46B | 28.10B |
| PurchaseOfInvestment | -10.31B | -31.18B | -38.78B | -47.61B |
| NetBusinessPurchaseAndSale | 7.04B | -43.43B | -23.00B | 0.00 |
| SaleOfBusiness | 7.04B | 0.00 | 0.00 | |
| PurchaseOfBusiness | 0.00 | -43.43B | -23.00B | 0.00 |
| NetPPEPurchaseAndSale | -2.91B | -3.91B | -3.24B | -2.71B |
| PurchaseOfPPE | -2.91B | -3.91B | -3.24B | -2.71B |
| OperatingCashFlow | 12.74B | 8.70B | 29.27B | 32.58B |
| CashFromDiscontinuedOperatingActivities | 0.00 | 0.00 | -343.00M | |
| CashFlowFromContinuingOperatingActivities | 12.74B | 8.70B | 29.27B | 32.92B |
| ChangeInWorkingCapital | -3.07B | -2.17B | -5.64B | 12.80B |
| ChangeInOtherWorkingCapital | -1.34B | -982.00M | -545.00M | -1.17B |
| ChangeInOtherCurrentLiabilities | -3.12B | 595.00M | -1.45B | 18.72B |
| ChangeInOtherCurrentAssets | 3.38B | -663.00M | -4.51B | -1.06B |
| ChangeInPayablesAndAccruedExpense | -1.02B | -300.00M | 1.19B | 1.24B |
| ChangeInPayable | -1.02B | -300.00M | 1.19B | 1.24B |
| ChangeInAccountPayable | -1.02B | -300.00M | 1.19B | 1.24B |
| ChangeInInventory | -854.00M | -1.17B | -591.00M | -1.12B |
| ChangeInReceivables | -109.00M | 347.00M | 261.00M | -3.81B |
| ChangesInAccountReceivables | -109.00M | 347.00M | 261.00M | -3.81B |
| OtherNonCashItems | -2.27B | -4.28B | -400.00M | -4.70B |
| StockBasedCompensation | 877.00M | 525.00M | 872.00M | 1.18B |
| AssetImpairmentCharge | 4.24B | 9.61B | 1.73B | 276.00M |
| DeferredTax | -2.10B | -3.44B | -3.76B | -4.29B |
| DeferredIncomeTax | -2.10B | -3.44B | -3.76B | -4.29B |
| DepreciationAmortizationDepletion | 7.01B | 6.29B | 5.06B | 5.19B |
| DepreciationAndAmortization | 7.01B | 6.29B | 5.06B | 5.19B |
| EarningsLossesFromEquityInvestments | 0.00 | |||
| NetIncomeFromContinuingOperations | 8.05B | 2.17B | 31.40B | 22.46B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PFE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|